Studies from two centres have reported that contacts of patients identified as recently infected by RITA show high rates of HIV infection and that a strategy of intensifying contact tracing efforts for this group of patients may be indicated [8, 11]. This survey has a relatively small sample size and results could have been affected by sampling bias, as health professionals with RITA experience were potentially more likely to respond. Nevertheless, analysis revealed that replies were received from clinicians with different levels of clinical and RITA experience and from centres evenly distributed across E&NI. Furthermore, the questionnaire was piloted before launch, in order to reduce any misinterpretation of questions
by participants. Many centres and clinicians Osimertinib manufacturer across E&NI have now incorporated check details RITA into clinical practice with no reported patient adverse events. More collaborative work is required between the HPA, local laboratories and clinics in order to improve clinician and patient access to results. Further evaluation of RITA is underway and national guidance, especially with regard to using RITA as an additional tool for contact tracing, is urgently required. The authors would like to thank A.
M. Geretti and K. Manavi for their detailed feedback on the pilot to this survey and all healthcare professionals who participated. We would also like to thank all clinic and laboratory staff for continuing to support the RITA programme in E&NI. Conflicts of interest: None of the authors has a conflict of interest to declare. ”
“The proportion of people living with HIV/AIDS in the ageing population (> 50 years old) is increasing.
We aimed to explore the relationship between older age and treatment outcomes in HIV-positive persons from the Asia Pacific 6-phosphogluconolactonase region. Patients from the Australian HIV Observational Database (AHOD) and the TREAT Asia HIV Observational Database (TAHOD) were included in the analysis. We used survival methods to assess the association between older age and all-cause mortality, as well as time to treatment modification. We used regression analyses to evaluate changes in CD4 counts after combination antiretroviral therapy (cART) initiation and determined the odds of detectable viral load, up to 24 months of treatment. A total of 7142 patients were included in these analyses (60% in TAHOD and 40% in AHOD), of whom 25% were > 50 years old. In multivariable analyses, those aged > 50 years were at least twice as likely to die as those aged 30–39 years [hazard ratio (HR) for 50–59 years: 2.27; 95% confidence interval (CI) 1.34–3.83; HR for > 60 years: 4.28; 95% CI 2.42–7.55]. The effect of older age on CD4 count changes was insignificant (p-trend = 0.06). The odds of detectable viral load after cART initiation decreased with age (p-trend = < 0.0001). The effect of older age on time to first treatment modification was insignificant (p-trend = 0.21).